One-Year estimated GFR Slope Independently Predicts Clinical Benefit in Immunoglobulin A Nephropathy
Kidney Int Rep
.
2022 Sep 29;7(12):2730-2733.
doi: 10.1016/j.ekir.2022.09.017.
eCollection 2022 Dec.
Authors
Richard A Lafayette
1
,
Heather N Reich
2
,
Andrew M Stone
3
,
Jonathan Barratt
4
Affiliations
1
Division of Nephrology, Department of Medicine, Stanford University, Stanford, California, USA.
2
Department of Medicine, Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
3
Stone Biostatistics Ltd., Crewe, UK.
4
College of Medicine Biological Sciences and Psychology, University of Leicester, Leicester, UK.
PMID:
36506237
PMCID:
PMC9727523
DOI:
10.1016/j.ekir.2022.09.017
No abstract available
Keywords:
IgA nephropathy; UPCR; eGFR; end-stage kidney disease; proteinuria; surrogate endpoint.